A Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma
A Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma
Active, not recruiting · NCT05551936 · Registry updated 2026-02-17Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, follicular lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 1 / Phase 2 | 2026-02-17 | NCT05551936 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Epizyme, Inc. | 8 |
| University of Wisconsin, Madison | 265 |
| Vaishalee Kenkre | 1 |
5 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Northwestern University | Chicago | United States | 727 |
| Ohio State University Comprehensive Cancer Center | Columbus | United States | 548 |
| Rutgers Cancer Institute of New Jersey | New Brunswick | United States | 223 |
| University of Illinois Cancer Center | Chicago | United States | 34 |
| University of Wisconsin Carbone Cancer Center | Madison | United States | 14 |